Economic analysis of newer antiepileptic drugs.
In the last 20 years, several second-generation antiepileptic drugs (AEDs) have been marketed. These newer drugs are expensive and have no established superiority over the first-generation compounds in terms of efficacy when used as monotherapy. A systematic review of economic studies dealing with the newer AEDs has been performed to put these drugs in a wider perspective. A number of economic analysis studies of second-generation AEDs have examined these compounds as monotherapy or adjunctive therapy. Almost all monotherapy studies showed newer AEDs as having similar effectiveness but significantly higher acquisition costs than first-generation drugs. The evidence from adjunctive therapy studies was more conflicting. Lamotrigine appeared to be a cost-effective drug when higher thresholds were used, or when savings were defined by the cost of surgery. Levetiracetam also appeared to be cost effective when the costs of surgical investigation were discounted.In a decision model that included quantification of the uncertainty associated with the decision regarding the cost effectiveness of AEDs, second-generation drugs used as monotherapy for newly diagnosed partial epilepsy produced similar benefits but were more expensive than older drugs. The newer AEDs were more effective but more expensive than existing monotherapies in patients with refractory partial epilepsy, but may be cost effective at higher thresholds, and continue to be cost effective in patients responding to the assigned drug. In patients with newly diagnosed generalized epilepsy, valproate was more cost effective than lamotrigine.The results of current economic studies are difficult to assess and compare because of a number of methodological drawbacks. Future studies should be implemented using a standardized approach to define the costs and outcomes of representative cohorts of patients with newly diagnosed epilepsy recruited from different countries and followed prospectively.
Beghi
Ettore
E
Laboratorio di Malattie Neurologiche, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. beghi@marionegri.it
Atzeni
Lucia
L
Garattini
Livio
L
D000927:Anticonvulsants / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000191:economics; D004827:Epilepsy / Q000188:drug therapy* / Q000191:economics; D006801:Humans
D000927:Anticonvulsants
Epilepsia. 1994 Nov-Dec;35(6):1230-43
7988516
Pharmacoeconomics. 2003;21(5):315-26
12627985
Epilepsia. 1998;39 Suppl 3:S19-25
9593232
Seizure. 1998 Apr;7(2):119-25
9627202
Epilepsia. 2000;41 Suppl 5:S37-44
11045437
Seizure. 1999 Feb;8(1):8-13
10091841
Seizure. 1995 Mar;4(1):37-44
7788105
Pharmacoeconomics. 2005;23(5):493-503
15896100
Epilepsia. 2006 Jul;47(7):1094-120
16886973
Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv
15842952
Drugs Today (Barc). 2004 Apr;40(4):325-42
15190386
Lancet. 2007 Mar 24;369(9566):1016-26
17382828
Med Decis Making. 2005 Sep-Oct;25(5):493-510
16160206
Epilepsia. 2002;43 Suppl 4:17-24
12059997
Eur J Health Econ. 2003 Nov;4(4):271-8
15609195
Arch Neurol. 2004 Sep;61(9):1361-5
15364680
Lancet. 2007 Mar 24;369(9566):1000-15
17382827
Seizure. 2007 Jun;16(4):296-304
17267243
Epilepsy Res. 2002 Feb;48(3):207-16
11904239
Epilepsia. 2001 May;42(5):641-6
11380572
Epilepsia. 1997 Aug;38(8):859-80
9579887
Neurology. 1998 Oct;51(4):1026-33
9781524
Ann Neurol. 2001 Mar;49(3):336-44
11261508
Epilepsia. 2004 Feb;45(2):171-8
14738425
Seizure. 1996 Jun;5(2):89-95
8795122